Partial
Partially Aligned
Patient Risk:
Low
Summary
Only portions of the indication-related claims are supported by the provided FDA label text (premenopausal women with acquired, generalized HSDD and exclusion of certain alternative causes). Claims about EU marketing authorization, EMA timelines, and country-level availability are not supported by the provided label sections.
Category Scores
Accurate Statements
The EU indication is for premenopausal women with HSDD who have an acquired, generalized lack of sexual desire.
Supported by provided label section 1 INDICATIONS AND USAGE describing indication for premenopausal women with acquired, generalized HSDD characterized by low sexual desire with marked distress or interpersonal difficulty.
The EU indication requires that other causes have been excluded.
Supported by provided label section 1 INDICATIONS AND USAGE stating HSDD is NOT due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.
In Europe, the approved indication is for premenopausal women diagnosed with acquired, generalized HSDD when other medical or psychiatric causes have been ruled out.
Partially supported by provided label section 1 INDICATIONS AND USAGE specifying not due to a co-existing medical or psychiatric condition (also not due to relationship problems or medication/drug effects).
Unsupported Statements
Vyleesi (bremelanotide) has marketing authorisation in the European Union (EU).
No EU marketing authorization information is present in the provided label sections.
In the EU, Vyleesi (bremelanotide) is authorized for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).
The provided label text does not include statements about EU authorization or scope.
The European marketing authorisation date is the same as the EU’s approval timeline for Vyleesi by the European Medicines Agency (EMA).
No EMA or EU approval timeline/date information is present in the provided label sections.
Even with EU marketing authorisation, availability of Vyleesi can differ by country because local health authorities decide on pricing, reimbursement, and how prescribing is implemented.
No information about country-by-country availability, pricing, reimbursement, or prescribing implementation is present in the provided label sections.
Contradictions
Important Omissions
If the goal is to substantiate EU authorization specifics (e.g., EU approval date/timeline), the provided label sections contain no such information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only on-label content addressed is an indication description. EU regulatory/availability statements are unsupported by the provided label but do not introduce direct dosing or safety claims in the extracted statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims reference EU marketing authorization, EMA timelines, and country availability that are not supported by the provided FDA label sections.
Suggested Improvement
Limit claims to the provided label-supported indication language (premenopausal women with acquired, generalized HSDD characterized by distress/interpersonal difficulty and not due to specified alternative causes). Remove or source separately any EU/EMA authorization timeline and country availability statements.